Agonist specific regulation of G protein-coupled receptors after chronic opioid treatment

Sweta Adhikary¹, Omar Koita¹, Joseph J. Lebowitz¹, William T. Birdsong², John T. Williams¹

¹ Vollum Institute, Oregon Health and Science University, Portland, OR 97239

² Department of Pharmacology, University of Michigan, Ann Arbor, United States

Running title: Agonist specific regulation following chronic opioids

Corresponding Author: John T Williams

Vollum Institute L474

Oregon Health & Science University

3181 SW Sam Jackson Park Rd.

Portland, OR 97239

Ph: (503) 494-4723

Fax: (503) 494-6972

Email: williamj@ohsu.edu

Pages: 28

Abstract: 198

Introduction: 516

Discussion: 1347

Figures: 7

Abbreviations: ACSF, artificial cerebrospinal fluid; LC, locus coeruleus; GRK, G protein-coupled receptor kinase; GIRK, G protein-coupled inwardly-rectifying potassium channel; ME, [Met⁵]enkephalin; MOR, μ -opioid receptor; MTA, morphine treated animal; TPD, total phosphorylation-deficient; CMP101, compound 101; PKC, protein kinase C; JNK, c-Jun N-terminal kinase; SST, somatostatin;

Abstract

Chronic treatment of animals with morphine results in a long-lasting cellular tolerance in the locus coeruleus (LC) and alters the kinase dependent desensitization of opioid and non-opioid GPCRs. This study examined the development of tolerance and altered regulation of kinase activity after chronic treatment of animals with clinically relevant opioids that differ in efficacy at the μ -opioid receptors (MOR). In slices from oxycodone treated animals, no tolerance to opioids was observed when measuring the MOR induced increase in potassium conductance but the G protein Receptor Kinase 2/3 (GRK2/3) blocker, compound 101, no longer inhibited desensitization of somatostatin (SST) receptors. Chronic fentanyl treatment induced a rightward shift in the concentration response to ME, but there was no change in the kinase regulation of desensitization of the SST receptor. When total phosphorylation deficient (TPD) MORs that block desensitization, internalization, and tolerance were virally expressed, chronic treatment with fentanyl resulted in the altered kinase regulation of SST receptors. The results suggest that sustained opioid receptor signaling initiates the process that results in altered kinase regulation of not only opioid receptors, but also other GPCRs. This study highlights two very distinct downstream adaptive processes that are specifically regulated by an agonist dependent mechanism.

Significance

Persistent signaling of MORs results in altered kinase regulation of non-opioid GPCRs after chronic treatment with morphine and oxycodone. Profound tolerance develops after chronic treatment with fentanyl without affecting kinase regulation. The homeostatic change in the kinase regulation of non-opioid GPCRs could account for the systems level in vivo development of tolerance that is seen with opioid agonist such as morphine and oxycodone that develop more rapidly than the tolerance induced by efficacious agonist such as fentanyl and etorphine.

Introduction

Opioids are widely used for pain management and they exert both their analgesic and rewarding effects through the activation of the μ -opioid receptors (MOR, Matthes et al. 1996). Agonist-bound MORs undergo regulatory processes that include desensitization and internalization that are thought to be proximal to the development of cellular tolerance. Both desensitization and internalization of MORs are agonist specific. High efficacy ligands like [Met⁵]enkephalin (ME) and fentanyl cause robust desensitization and receptor internalization while low efficacy agonists morphine and oxycodone cause less desensitization and internalization but may induce counter-regulatory and homeostatic adaptations (Harris and Williams 1991; Fiorillo and Williams 1996; Alvarez et al. 2002; Bailey et al. 2003; Dang and Williams 2004; Johnson et al. 2006; Virk and Williams 2008). Consequently, long-term treatment with agonists of different efficacy could result in unique adaptations at the cellular level, leading to differences in cellular tolerance.

Cellular tolerance is defined by a loss of receptor function after long-term agonist exposure. This loss of function can result from a decrease in receptor/effector coupling, internalization, or down regulation. In locus coeruleus (LC) neurons, chronic morphine treatment results in increased desensitization of MORs and a long-lasting reduction in MOR efficacy that persists even in the absence of morphine (Bailey et al. 2009; Levitt and Williams 2012). Additionally, chronic morphine treatment alters the kinase regulation of MORs and somatostatin (SST) receptors, both of which are class A GPCRs. In opioid naïve animals, inhibition of G protein receptor kinase 2/3 (GRK2/3) with compound 101 inhibits SST receptor desensitization; however, in chronic morphine treated animals, the concurrent inhibition of GRK2/3, protein kinase C (PKC) and c-Jun kinase (JNK) was required to prevent desensitization of SST receptors (Leff, Arttamangkul, and Williams 2020). These findings suggest that chronic morphine treatment alters kinase regulation of LC neurons such that additional kinases are upregulated to induce desensitization of both MORs and SST receptors. The mechanism that underlies the altered kinase regulation is not known.

The present study aimed to evaluate the differential effects of chronic treatment by opioids that are commonly used in clinic. Animals were treated for 6-7 days with one of several opioid agonists that had varying efficacies to investigate the role of efficacy in the development of

cellular tolerance and kinase-dependent regulation of desensitization. Cellular tolerance was assessed using whole-cell voltage-clamp recordings from LC neurons. The results show that chronic treatment with oxycodone does not induce cellular tolerance to opioids, whereas chronic treatment with fentanyl results in profound opioid tolerance. The altered regulation of the ability of kinase inhibitors to block desensitization of the SST receptor was examined with the GRK2/3 inhibitor compound 101. The results demonstrate that chronic treatment with both morphine and oxycodone, but not fentanyl or buprenorphine, altered the kinase regulation of SST receptor desensitization. Thus, not only was there an agonist selective action on the development of cellular tolerance and the induction of an altered kinase regulation of desensitization, but there was a distinct difference in the ability of agonists to affect the two processes.

Materials and Methods

Drugs

Morphine sulfate, Oxycodone, Fentanyl, and Buprenorphine were obtained from the National Institute on Drug Abuse, Neuroscience Center (Bethesda, MD). [Met]5 enkephalin (ME), bestatin, thiorphan, and idazoxan were from Sigma-Aldrich (St. Louis, MO). SST was from ProSpec (ProSpec-Tany TechnoGene Ltd., Rehovot, Israel). MK-801 (5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate) and compound 101 (CMP101, 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-N-[[2-(trifluoromethyl)phenyl]methyl]benzamide hydrochloride) were purchased from Hello Bio (Princeton, NJ); UK14304 tartate (5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline) was from Tocris (Bio-Techne Corp., Minneapolis, MN). Potassium methanesulfonate was acquired from Alfa Aesar (Ward Hill, MA). SST, ME, UK, and idazoxan were dissolved in water, diluted to the appropriate concentration in ACSF, and applied by superfusion. CMP101 was first dissolved in DMSO (10% of final volume), sonicated, and then brought to its final volume with 20% (2-Hydroxypropyl)- β -cyclo-dextrin (Sigma-Aldrich) and sonicated again to create a 10mM solution. Slices were incubated in CMP101 (30 μ M) diluted in artificial cerebrospinal fluid (ACSF) for at least 1 hour prior to recording, and CMP101 included in the bath (1 μ M) and drug solutions (10 μ M).

Animals

Adult rats of both sexes were used with ages between 5 and 8 weeks for all experiments. Wild-type Sprague-Dawley rats were obtained from Charles River Laboratories (Wilmington, MA), MOR-knockout Sprague-Dawley rats were used as described in Arttamangkul et al. (2019). All animal experiments were conducted in accordance with the National Institutes of Health guidelines and with approval from the Institutional Animal Care and Use Committee of the Oregon Health & Science University (Portland, OR).

Viral Injections

MOR-knockout animals (P24-30) were anesthetized with isoflurane and placed in a stereotaxic frame for microinjection of adenoassociated virus type 2 (AAV2) encoding virally expressed total phosphorylation-deficient MORs (TPD, AAV2- CAG-SS-GFP-MOR-TPD-WPRE-SV40pA, Arttamangkul et al., 2018; 2019) in the LC. A total of 200 nl of virus was injected at 0.1 μ l/min bilaterally in the LC (anteroposterior: -9.72 mm, mediolateral: +/-1.25 mm, dorsoventral: -6.95 mm, from bregma). Both viruses were obtained from Virovek (Hayward, CA). Electrophysiology experiments were carried out at least two weeks following injection.

Chronic Opioid Treatment

Rats were treated with either morphine sulfate, oxycodone, fentanyl, or buprenorphine continuously released from osmotic pumps as described previously (Quillinan et al., 2011). In order to avoid overdose deaths, the treatment of animals with oxycodone and fentanyl required priming doses with intra-peritoneal (IP) injections prior to implantation of the osmotic mini pumps. Twice daily doses oxycodone: 5 mg/kg or fentanyl: 0.5 mg/kg were given for two days before implantation of the pumps. This procedure dramatically reduced the number of overdose deaths following implantation of the pumps. Thus by this very basic protocol it seems reasonable to conclude that at least acutely the dose of the two drugs was close to functionally equivalent. Osmotic pumps (2ML1; Alzet, Cupertino, CA) were filled with the required concentration of each drug in water to deliver, 80 mg/kg/day morphine, 30 mg/kg/day oxycodone, 1.5 mg/kg/day fentanyl, or 10 mg/kg/day buprenorphine. Each pump has a 2-ml reservoir that releases 10 μ l/h for up to 7 days. The dose of each agonist was chosen to induce the maximum amount of tolerance over the relatively short duration of application. Briefly, rats were anesthetized with

isoflurane, and an incision was made in the midscapular region for subcutaneous implantation of osmotic pumps. Pumps remained until animals were used for experiments 6 or 7 days later.

Tissue Preparation

Acute brain slice preparation was performed as previously described (Levitt and Williams, 2012). Briefly, rats were deeply anesthetized using isoflurane and euthanized by cardiac percussion. Brains were removed, blocked, and mounted in a vibratome chamber (VT 1200S; Leica, Nussloch, Germany). Horizontal LC slices (260 μ m) were prepared in warm (34°C) ACSF containing (in mM) 126 NaCl, 2.5 KCl, 1.2 MgCl₂, 2.6 CaCl₂, 1.2 NaH₂PO₄, 21.4 NaHCO₃, and 11 D-glucose with +MK-801 (10 μ M). Slices were allowed to recover in warm

ACSF containing +MK-801 (10 μ M) for at least 30 minutes or two hours for treated animals and then stored in glass vials with warm (34°C) oxygenated (95% O₂ / 5% CO₂) ACSF until used.

Electrophysiology

Slices were hemisected and then transferred to the recording chamber, which was continuously superfused with ACSF (1.5–2 ml/min, at 34°C). Whole-cell recordings from LC neurons were obtained with an Axopatch 200B amplifier (Axon Instruments) in voltage-clamp mode holding potential ($V_{\text{hold}} = -55$ mV). Recording pipettes (World Precision Instruments, Sarasota, FL) with a resistance of 1.0–1.5 M Ω were filled with an internal solution of (mM) 115 potassium methanesulfonate or potassium methyl sulfate, 20 NaCl, 1.5 MgCl₂, 5 HEPES(K), 10 BAPTA, 2 Mg-ATP, 0.2 NaGTP, pH 7.4, and 275–280 mOsm. Liquid junction potential (10 mV) was not corrected. Data were filtered at 10 kHz and collected at 20 kHz with AxographX or 400 Hz with PowerLab (Chart version 5.4.2; AD Instruments, Colorado Springs, CO). Only recordings in which the series resistance remained <14 M Ω were included).

Data Analysis

For all conditions, animals were used to obtain at least six technical replicates per group; if more than six could be analyzed, all were included. Analysis was performed by using GraphPad Prism 9 (GraphPad Software, version 9.0d; San Diego, CA) based on number of technical replicates (N = number of cells). Values are presented as mean $\pm$ SD. Statistical comparisons were made using

unpaired T-test, one-way or two-way ANOVA as well as multiple comparison adjusted Tukey's post hoc tests, as appropriate. Concentration response curves were constructed using GraphPad Prism 9 and the confidence interval (CI, 95%) for each curve were determined. For all experiments, $p < 0.05$ was used to define statistical significance.

RESULTS

Tolerance induced by chronic opioid treatment

Chronic treatment of rats with morphine has been shown to induce a twofold rightward shift of the concentration–response curve to the full MOR agonist DAMGO (D-Ala²-N-Me-Phe⁴-glycol⁵-enkephalin) and a decrease in the maximum current induced by the partial agonist, normorphine in locus coeruleus neurons (Christie, Williams, and North 1987). The present results aimed to determine the degree of tolerance induced by chronic treatment with two agonists with varying efficacies. Rats were implanted with osmotic pumps that continuously released oxycodone (30 mg/kg/day) or fentanyl (1.5 mg/kg/day). Brain slices were prepared in opioid free solution and washed for 90 min before making whole cell recordings.

Tolerance measured with ME

Concentration-response curves were created by measuring the outward current induced by ME in brain slices obtained from untreated, oxycodone, and fentanyl treated animals. The current induced by ME was normalized to that induced by a saturating concentration of the α_2 -adrenergic receptor agonist, UK14304 (3 μ M). In slices from opioid naïve rats, a saturating concentration of ME caused an outward current that was 128.9 ± 19 % of the current produced by UK14304 (Fig 1A, C). The concentration of ME that produced a half maximal outward current (EC_{50}) in slices

from control was 166 nM, 95% CI = 152-297 nM, N = 3 or 4 cells per concentration from 4 male and 5 female; Fig.1A, C). In slices from oxycodone-treated rats, the concentration response curve to ME was not different from that obtained in naive animals (EC_{50} = 179 nM, 95% CI = 117-280 nM; N = 3 to 5 cells per concentration from 6 male and 8 female; Fig 1C, two-way ANOVA, $p = 1.0$). In slices taken from fentanyl treated animals, however, there was a twofold rightward shift in ME concentration–response curve (EC_{50} = 518 nM, 95% CI = 496-646 nM; N = 50

3 to 5 cells per concentration from 6 male and 8 female; Fig 1B, C, two-way ANOVA, $p = 0.002$). The maximum current induced by ME was not different in slices from untreated, oxycodone treated, and fentanyl treated animals ($125.0 \pm 3.4\%$, $126.4 \pm 4.1\%$, and $134.5 \pm 7.1\%$, respectively (one-way ANOVA, $p = 0.13$). By this measure, the results indicated that treatment with fentanyl but not oxycodone resulted in tolerance to ME dependent activation of MORs in the LC. As previously reported for morphine treated animals, the current induced by UK14304 ($3\ \mu\text{M}$) was the same among the treatment groups (untreated: $235.5 \pm 99.7\ \text{pA}$ $n=10$; oxycodone treated: $221.0 \pm 90.0\ \text{pA}$, $n=17$; fentanyl treated: $198.2 \pm 87.8\ \text{pA}$, $n=19$; one-way ANOVA, $p = 0.19$).

Oxycodone treatment - Tolerance measured with oxycodone.

It is possible that tolerance to ME was not observed following oxycodone treatment due to the high efficacy of ME or a potential agonist specific action. Thus concentration-response curves to oxycodone were constructed in slices from untreated or oxycodone treated animals. The oxycodone concentration-response curves were created by normalizing the peak outward current amplitude induced by oxycodone to the current induced by a saturating concentration of UK14304 ($3\ \mu\text{M}$). A single concentration of oxycodone was tested in each slice. In slices from untreated animals, a saturating concentration of oxycodone caused an outward current that was $99.1 \pm 3.1\%$ of the current produced by UK14304, compared to $125.0 \pm 3.4\%$ for ME, demonstrating that oxycodone is a partial agonist in this assay (Fig.2A, C). The EC_{50} of

oxycodone was $2.5\ \mu\text{M}$ (95% CI = $1.1\text{--}5.5\ \mu\text{M}$; $N = 3$ to 5 cells per concentration from 4 male and 6 female; Fig.2A, C). In slices taken from oxycodone-treated animals (OTA), the concentration response to oxycodone was unchanged (saturating current $97.1 \pm 12.5\%$ of UK14304, $EC_{50} = 4.5\ \mu\text{M}$, 95% CI = $1.4\text{--}16.1\ \mu\text{M}$; $N = 3$ or 4 cells per concentration from 3

males and 6 female; Fig 2C, two-way ANOVA: main effect of concentration, $p < 0.01$, no effect of drug treatment, $p = 0.46$). Oxycodone treatment did not alter the average current induced by UK14304 (untreated: $194.6 \pm 61.9\ \text{pA}$, $N=6$, OTA: $257.9 \pm 50.9\ \text{pA}$, $N=13$ cells, unpaired t-test, $p > 0.05$). Thus, chronic treatment with oxycodone did not alter the sensitivity of MORs to either a subsequent challenge with ME or oxycodone suggesting that there was minimal cellular tolerance induced by 6-7 days of treatment with oxycodone.

In addition to long-lasting cellular tolerance induced by chronic morphine treatment, there is a short-lasting morphine-induced desensitization found in slices from morphine treated animals that were maintained in a morphine solution (Bailey, Oldfield, et al. 2009; Levitt and Williams 2012). To determine whether chronic oxycodone treatment could induce this short-term desensitization, LC brain slices were prepared and maintained in a solution containing oxycodone (1 μ M). Recordings were made in the continued presence of oxycodone, and the opioid antagonist naloxone (1 μ M) was applied to determine the steady-state oxycodone current (N = 8 cells from 1 male and 2 female; Fig. 2B, C). The amplitude of this oxycodone-mediated current was not different from the current produced by oxycodone (1 μ M) in slices from oxycodone treated animals that were prepared and maintained in drug free solution or in slices from untreated animals (OTA: Oxycodone 34.5 ± 11.3 % of UK14304; OTA, wash: 34.9 ± 6.1 % of UK14304; untreated: 35.8 ± 7.4 % of UK14304; Figure 1G, one-way ANOVA, $p > 0.05$).

Oxycodone treatment - Tolerance measured with morphine.

As a partial agonist, the current induced by morphine has been used as more sensitive assay to detect tolerance than higher-efficacy agonists (Christie, Williams, and North 1987). Therefore, the outward current induced by morphine (1 μ M) was examined in slices from animals treated with oxycodone or fentanyl. In slices from untreated animals, morphine (1 μ M) induced an outward current that was 66.7 ± 14.1 % of that produced by UK14304 (N = 11 cells from 3 male and 3 female; Fig. 3A, D). In slices from oxycodone-treated animals, morphine (1 μ M) induced outward current was not different as in slices from untreated animals (54.7 ± 9.0 %, one-way ANOVA, $p = 0.16$; N = 7 cells from 3 male and 2 female; Fig. 3B, D). Thus, chronic treatment with oxycodone did not change the sensitivity of MORs to morphine. In slices from fentanyl treated animals, however, the morphine induced current was reduced to 18.9 ± 13.8 % of the current induced by UK14304 (one-way ANOVA, $p < .001$; N = 10 cells from 4 male and 3 female; Fig. 3C, D). Thus, like the rightward shift in the concentration response curve to ME after treatment with fentanyl, there was a robust decrease in the current induced by morphine.

Increased acute ME induced MOR desensitization after chronic oxycodone treatment.

An increase in MOR desensitization after chronic morphine treatment is a measure of cellular tolerance (Quillinan et al., 2011). Therefore, experiments were designed to test if chronic oxycodone and fentanyl treatment increased MOR desensitization. A brief application of a saturating concentration of ME (10 μ M, 2 min) is enough to desensitize MORs measured using a subsequent application of morphine (Dang and Williams 2005). The present experiments examined the current induced by oxycodone (10 μ M) or morphine (10 μ M) in slices from oxycodone or fentanyl treated animals respectively following application of saturating concentration of ME. Following the application of ME (10 μ M, 2 min), oxycodone (10 μ M) or morphine (10 μ M) were applied. The morphine or oxycodone induced current was normalized to that induced by UK14304 (3 μ M). In slices from untreated animals, the current induced by oxycodone (10 μ M) after ME application was decreased to 54.0 ± 10 % of UK14304 (Fig 4C, N = 6 cells from 3 male and 2 female) from 89.4 ± 15.4 % without pre-application of ME (Fig 2C, N = 5 cells from 2 males 2 female). In slices from oxycodone treated animals the current following application of ME was the same as that in untreated animals (OTA: 54.0 ± 10.0 % of UK14304; n = 5 cells from 1 male and 3 female; Fig. 4C, $p > 0.05$, unpaired t-test).

In slices from fentanyl treated animals, morphine (10 μ M) was applied following the application of ME (10 μ M, 2 min). In slices from untreated animals, the current induced by morphine (10 μ M) decreased to 58.5 ± 7.9 % of UK14304 (Fig 4A, C; N = 6 cells from 3 male and 2 female rats) relative to the published value of 76 ± 3 % (Levitt and Williams, 2012). In slices from fentanyl treated animals, following ME pre-application the morphine current decreased to 32.7 ± 5.2 % of UK14304 (Fig 4B, C; N = 6 cells from 3 male and 2 female; $p < 0.05$, unpaired t-test). The results indicated that chronic fentanyl treatment decreases MOR-effector coupling, unlike after chronic oxycodone treatment. The current induced by a saturating concentration of ME (10 μ M) was not different in slices from untreated, oxycodone treated, and fentanyl treated animals (untreated: 120.5 ± 11.6 %, N=6, oxycodone treated: 132.9 ± 22.0 %, N = 5, fentanyl treated: 119.3 ± 17.7 %, N = 6; $p > 0.05$; one-way ANOVA Dunnett post hoc). Thus, as determined by several measures, the results indicate that the degree of tolerance induced by chronic treatment with oxycodone and fentanyl differ substantially.

Agonist-specific kinase adaptations.

The SST receptor activates the same potassium conductance as opioids in LC neurons (Fiorillo and Williams 1996). The current induced by SST (10 μ M, 10 min) peaks and declines and was taken as a measure of acute desensitization. Like MORs, SST receptors are phosphorylated by GRK2/3 (Günther et al. 2018) and inhibition of GRK2/3 with compound 101 decreased SST receptor desensitization (Leff, Arttamangkul, and Williams 2020). In slices taken from animals chronically treated with morphine, compound 101 alone was no longer sufficient to block acute SST induced desensitization (Leff, Arttamangkul, and Williams 2020). Instead, the combination of kinase inhibitors, acting at GRK2/3, PKC and JNK were required to block SST induced desensitization. Thus, chronic morphine treatment altered the kinase dependence of GPCRs in LC neurons.

In the present study, animals were chronically treated with morphine, oxycodone, fentanyl or buprenorphine to investigate the agonist specific regulation of SST desensitization by kinases. In untreated animals, the current induced by SST (10 μ M) declined to $32.7 \pm 13.1\%$ of the peak after 10 mins (N = 14 cells from 5 male and 7 female; Fig. 5C). In slices that were incubated with compound 101 the decline was reduced to $63.7 \pm 6.8\%$ of the peak (N = 11 cells from 5 male and 5 female; Fig. 5C). Thus, the inhibition of GRK 2/3 alone is sufficient to decrease acute SST-induced desensitization in untreated animals. (Fig 5C; $p < 0.01$, unpaired t-test). As previously reported (Leff et al., 2020), in slices from morphine treated animals, the decline in the current induced by SST was insensitive to compound 101 (without compound 101: $35.8 \pm 8.0\%$ percent of peak, N = 7 cells from 3 male and 3 female; in compound 101: $33.2 \pm 12.2\%$, N = 7 cells from 3 male and 3 female; Fig. 5C; $p > 0.05$, unpaired t-test).

As was found with the morphine treated animals, in slices from oxycodone treated animals, compound 101 alone did not block the SST induced desensitization (without compound 101: $37.07 \pm 15.9\%$, N = 7 cells from 3 male and 1 female; in compound 101: $38.1 \pm 15.5\%$, N = 6, 3 male and 1 female; Fig. 5A, C, $p > 0.05$, unpaired t-test). However, in slices from buprenorphine treated animals, similar to untreated animals, compound 101 inhibited SST receptor desensitization (without compound 101: $30.4 \pm 15.8\%$, N = 9 cells from 3 male and 3 female; in compound 101: $64.7 \pm 7.7\%$, N = 13 cells in 5 male and 4 female; Fig. 5C; $p < 0.05$, unpaired t-test). The same result was obtained using slices from fentanyl treated animals. Compound 101

inhibited SST receptor desensitization (without compound 101: 27.5 ± 3.6 %, N = 9 cells from 4 male and 3 female; in compound 101: 67.1 ± 13.0 , N = 8 cells in 3 male and 6 female; Fig. 5B, C; $p < 0.05$, unpaired t-test). Therefore, the opioid-induced regulation of kinase signaling in the locus coeruleus after chronic treatment with morphine and oxycodone is agonist specific. These agonists have moderate efficacy and are inefficient at the induction of receptor internalization. However, chronic treatment with buprenorphine and fentanyl result in no change in kinase regulation in spite of the fact that the efficacy of these agonist is very different.

Sustained signaling of MORs and GRK2/3 dependent SST receptor desensitization

The opioid agonist dependent changes to LC kinase activity measured with the desensitization induced by SST could result from at least two mechanisms: (1) continued opioid receptor activation or (2) opioid receptor internalization. Current interest in agonist selective actions has centered on agonists that selectively activate G protein or arrestin dependent pathways (biased signaling, reviewed Birdsong and Williams, 2020). A number of biased agonists have been reported however no agonist has been found to be completely biased (Gillis, Gondon et al., 2020; Gillis, Kliewer et al., 2020). One potential way to distinguish the two pathways is through the elimination of MOR receptor phosphorylation (Kliewer et al., 2019). A receptor with alanine mutation of all 11 phosphorylation sites of the c-terminal tail of MOR, termed the Total Phosphorylation Deficient (TPD) receptor eliminated MOR desensitization and internalization without attenuating G-protein mediated signaling (Arttamangkul et al. 2018; Kliewer et al., 2019). To address the two potential mechanisms that induce alterations in kinase activity following chronic opioids, the phosphorylation-deficient MOR (TPD-MOR) was expressed in the LC of MOR knockout rats.

First MOR KO animals were treated with morphine and the desensitization induced by SST in the absence and presence of compound 101 was examined. In these experiments compound 101 was still able to inhibit SST receptor desensitization, indicating that the change in kinase regulation was dependent on the activation of MORs (without 101: 38.0 ± 10.2 % percent of peak, N = 6 cells from 2 male and 3 female; in compound 101: 63.0 ± 9.1 %, N = 6 cells from 2 male and 3 female; Fig 6A, B, C).

Next, TPD-MOR expressing MOR knockout animals were treated with fentanyl and the action of compound 101 on SST receptor desensitization was assessed. In untreated MOR KO animals expressing the TPD-MOR, SST induced desensitization was robust and sensitive to compound 101 (without compound 101: percent peak 26.6 ± 10.8 %, N = 9 cells from 2 male and 3 female; in compound 101: 67.0 ± 5.8 %, N = 9 cells in 2 male and 1 female; Fig. 7A, C; $p > 0.05$, unpaired t-test). In fentanyl treated animals, however, the SST receptor desensitization was insensitive to compound 101 (without compound 101: percent peak 29.6 ± 11.4 %, N = 6 cells from 3 male and 1 female; in compound 101: 31.5 ± 11.9 %, N = 7 cells in 2 male and 2 female; Fig. 7B, C; $p > 0.05$, unpaired t-test). This result is the same as the results obtained using WT animals treated with morphine or oxycodone. Thus, sustained signaling of MORs was sufficient to alter the kinase regulation that modulated SST receptor desensitization and suggests that desensitization and/or internalization may prevent these adaptations. Taken together the results indicate that treatment with fentanyl in wild type animals induced cellular tolerance to reduce signaling such that downstream adaptive mechanisms underlying the altered kinase regulation were not engaged.

Discussion

The present study found that chronic treatment of rats with different opioid agonists had markedly different actions that were dependent on the agonist. Both the degree of tolerance measured by MOR activation of potassium conductance and the GRK2/3 dependent desensitization of a non-opioid receptor were affected differently depending on the agonist treatment. Chronic treatment with oxycodone did not induce desensitization or measures of tolerance, but resulted in a decrease in the ability of the GRK2/3 inhibitor compound 101 to block acute desensitization of the SST receptor. Chronic treatment with fentanyl induced robust tolerance and increased MOR desensitization, but had no effect on the ability of compound 101 to block desensitization of the SST receptor. Previous work has shown that with viral expression of TPD-MORs in MOR knockout rats, acute desensitization, trafficking and tolerance are drastically decreased (Arttamangkul et al. 2018). In this study, treatment of MOR knockout animals expressing the TPD receptor with fentanyl resulted in an inability GRK2/3 inhibition alone to regulate SST receptor desensitization. This observation is the opposite of that seen in fentanyl treated wild type animals and is the same as in animals treated with oxycodone and

morphine. Taken together, the results suggest that sustained signaling from the plasma membrane is the underlying process that initiates the altered LC kinase signaling.

Agonist specific regulation after chronic treatment

Chronic opioid treatment results in a variable amount of tolerance that is dependent on agonist efficacy, the measure of tolerance and details of the treatment protocol (reviewed – Williams et al. 2013; reviewed – Morgan and Christie 2011). When measuring the antinociceptive action of opioids using the tail flick assay, chronic treatment with oxycodone or etorphine administered with osmotic mini pumps induced tolerance to oxycodone more quickly than that to etorphine (Pawar et al. 2007; Madia et al. 2009). Similar results were obtained in animals treated with a variety of opioids, where morphine and oxycodone resulted in a larger shift in the dose response curve than fentanyl measured also using a tail flick assay (He et al. 2021). The conclusion was the analgesic tolerance induced by high efficacy agonists developed slower than with treatment with lower efficacy agonists. Using a paw withdrawal assay, however, chronic treatment with fentanyl induced a larger rightward shift in the dose response than morphine (Kliwer et al. 2019).

A large component of the analgesic tolerance induced by chronic opioid treatment results from homeostatic compensatory mechanisms (reviewed – Christie 2008; reviewed –Williams et al. 2013). These compensatory mechanisms underlie acute withdrawal that is induced by treatment with naloxone. Previous studies have suggested that the compensatory mechanisms are more prevalent with the use of agonists that are less effective at the induction of desensitization or tolerance or when MOR phosphorylation is inhibited (Kliwer et al. 2019). Thus, when comparing in vivo tolerance and cellular tolerance, compensatory mechanisms likely underlie difference in measures between the two assays.

Agonist regulation of kinase dependent desensitization

The interaction between arrestin, GRK2/3, and MOR signaling has received considerable interest as one mechanism that underlies biased signaling. Phosphorylation of the receptor is the first and necessary step in the recruitment of arrestin to MOR (Gillis, Kliwer, et al. 2020). The GRK/GPCR interaction is transient, dependent on agonist/receptor association and

phosphorylation of the receptor at multiple sites most likely requires multiple binding interactions between GRK and the receptor (Gurevich and Gurevich 2019). The inability of morphine and oxycodone to recruit arrestin is certainly dependent on the lack of receptor phosphorylation induced by morphine and oxycodone (Gillis, Gondin, et al. 2020). In fact, with the over expression of GRK2, the recruitment of arrestin by all agonists is augmented (Gillis, Gondin, et al. 2020). Thus, the regulation of GRK2/3 activity, along with PKC and JNK, will have a dramatic action on desensitization that is dependent on the recruitment of arrestin.

Persistent signaling gates adaptive mechanisms

Although chronic oxycodone did not induce cellular tolerance, the continued activation of the receptor resulted in a downstream alteration of kinase activity. The combination of kinase inhibitors that acted on PKC and JNK and GRK2/3 were required to block desensitization of the SST receptor after chronic morphine treatment (Leff, Arttamangkul, and Williams 2020). Given that both morphine and oxycodone do not effectively recruit GRK2/3, the fact that other kinases are upregulated after chronic treatment is consistent with work indicating that morphine induces receptor phosphorylation by PKC (Bailey, Kelly, and Henderson 2004; Johnson et al. 2006; Bailey, Llorente, et al. 2009; Bailey, Oldfield, et al. 2009; Levitt and Williams 2012). This modulation is surely dependent on persistent activation of MORs, as TPD-MOR after treatment with fentanyl also alters the kinase signaling in the LC. Thus, agonist efficacy alone does not account for the downstream adaptation of kinase activity.

Buprenorphine is a weak partial agonist of the MORs that induced a hyperpolarization in LC neurons (Virk et al. 2009). Buprenorphine, like morphine and oxycodone, does not recruit GRK and therefore arrestin to induce acute desensitization or receptor internalization. It appears that while the outcomes of chronic treatment with buprenorphine and fentanyl are the same, it is likely that this results from different mechanisms. The low intrinsic efficacy of buprenorphine results in a low level of receptor activation that may not effectively result in downstream regulation of kinases. In that way it may be similar to results obtained with fentanyl treated animals where the receptor signaling is compromised by the development of tolerance (He et al, 2021).

Although inhibition of GRK2/3 alone in slices from morphine treated animals was not sufficient to block desensitization of the SST receptor, the inhibition of a series of other kinases including GRK2/3 did block desensitization (Leff, Arttamangkul, and Williams 2020). Thus, GRK2/3 remained active, but inhibition of it alone was ineffective in blocking desensitization following an apparent up regulation of PKC and JNK. The change in kinase regulation was dependent on an increase in the ability of other kinases that may phosphorylate MORs and SST receptors or an auxiliary protein that mediates desensitization (Yousuf et al. 2015). In our hands, inhibition of PKC had little or no effect on desensitization of MORs in untreated animals (Levitt and Williams 2012; Arttamangkul, Birdsong, and Williams 2015), however there was a component of short-term tolerance that was sensitive to inhibition of PKC in slices from morphine treated animals (Levitt and Williams 2012). In addition, the inhibition of JNK resulted in a block in acute desensitization at the spinal level (Melief et al. 2010). Thus, there is evidence that multiple kinases can underlie acute MOR desensitization. However, neither PKC nor JNK alone had an effect in MOR or SST receptor desensitization in LC neurons from untreated or morphine treated animals (Leff, Arttamangkul, and Williams 2020). Therefore, the conclusion of the present work is that following treatment of animals with moderate-efficacy opioids, multiple kinases are engaged to mediate acute desensitization of MORs and other GPCRs, and the engagement of these kinases is dependent on sustained signaling.

Summary

The present work distinguishes both receptor-level regulation and a downstream adaptation induced by opioid agonists with varying efficacies after chronic treatment. Chronic oxycodone treatment did not induce cellular tolerance, unlike the profound tolerance induced by chronic treatment with fentanyl. Alternatively, chronic oxycodone treatment, but not chronic fentanyl treatment, induced a decrease in the ability of GRK2/3 inhibition to prevent acute desensitization, and this adaptation included the desensitization of the SST receptor. Although dose equivalence of different opioid agonists used for chronic treatment was not established, the experiments with the TPD-MOR expressing neurons following chronic treatment with fentanyl indicates that the adaptive changes (measures of tolerance and altered kinase regulation) were receptor dependent rather than the dose used for treatment. When internalization was blocked using expression of the TPD MOR and animals were treated with fentanyl, sustained signaling

promoted the altered kinase regulation of SST receptors. Taken together the results suggest that a) agonists with different efficacy differentially regulate MOR and thus cellular tolerance and b) though inhibiting phosphorylation may reduce one measure of tolerance, persistent signaling induced by these receptors can lead to downstream adaptations like upregulation of PKC and JNK that promote other measures of cellular and systemic tolerance that may underlie opioid withdrawal. The consequence is that signaling at the cellular level following chronic opioid treatment affects desensitization of GPCRs beyond the opioid receptors.

Acknowledgments: We would like to thank Seksiri Arttamangkul and Erica Levitt for helpful discussions.

Author Contributions:

Participated in research design: Adhikary, Williams, Birdsong

Conducted experiments: Adhikary, Williams, Lebowitz, Koita

Performed data analysis: Adhikary

Wrote or contributed to writing the paper: Adhikary, Williams, Birdsong

References

- Alvarez VA, Arttamangkul S, Dang V, Salem A, Whistler JL, Von Zastrow M, Grandy DK, Williams JT (2002) μ -Opioid Receptors: Ligand-Dependent Activation of Potassium Conductance, Desensitization, and Internalization. *J Neurosci* **22**: 5769-5776. <https://doi.org/10.1523/jneurosci.22-13-05769.2002>
- Arttamangkul S, Birdsong W, Williams JT (2015) Does PKC Activation Increase the Homologous Desensitization of μ Opioid Receptors? *Brit J Pharmacol* **172**: 583-592. <https://doi.org/10.1111/bph.12712>.
- Arttamangkul S, Heinz DA, Bunzow JR, Song X, Williams JT (2018) Cellular Tolerance at the M-Opioid Receptor Is Phosphorylation Dependent. *eLife* <https://doi.org/10.7554/eLife.34989>.
- Arttamangkul S, Leff ER, Koita O, Birdsong WT, Williams JT (2019) Separation of acute desensitization and long-term tolerance of μ -opioid receptors is determined by the degree of C-terminal phosphorylation, *Mol Pharmacol* **96**: 505-514.
- Bailey CP, Llorente B, Gabra BH, Smith FL, Dewey WL, Kelly E, Henderson G (2009) Role of Protein Kinase C and μ -Opioid Receptor (MOPr) Desensitization in Tolerance to Morphine in Rat Locus Coeruleus Neurons. *E J Neurosci* **29**: 307–18. <https://doi.org/10.1111/j.1460-9568.2008.06573.x>.
- Bailey CP, Oldfield S, Llorente J, Caunt CJ, Teschemacher AG, Robers L, McArdle CA (2009) Involvement of PKC α and G-Protein-Coupled Receptor Kinase 2 in Agonist-Selective Desensitization of μ -Opioid Receptors in Mature Brain Neurons. *Brit J Pharmacol* **158**: 157-164. <https://doi.org/10.1111/j.1476-5381.2009.00140.x>.
- Bailey CP, Couch D, Johnson E, Griffiths K, Kelly E, Henderson G (2003) μ -Opioid Receptor Desensitization in Mature Rat Neurons: Lack of Interaction between DAMGO and Morphine. *J Neurosci* **23**: 10515-10520. <https://doi.org/10.1523/JNEUROSCI.23-33-10515.2003>.

Bailey CP, Kelly E, Henderson G (2004) Protein Kinase C Activation Enhances Morphine-Induced Rapid Desensitization of μ -Opioid Receptors in Mature Rat Locus Coeruleus Neurons. *Mol Pharmacol* **66**: 1592-1598. <https://doi.org/10.1124/mol.104.004747>.

Birdsong WT, Williams JT (2020) Recent Progress in Opioid Research from an Electrophysiological Perspective. *Mol Pharmacol* **98**: 401 – 409.
<https://doi.org/10.1124/mol.119.119040>

Christie MJ (2008) Cellular Neuroadaptations to Chronic Opioids: Tolerance, Withdrawal and Addiction. *Brit J Pharmacol* <https://doi.org/10.1038/bjp.2008.100>.

Christie MJ, Williams JT, North RA (1987) Cellular Mechanisms of Opioid Tolerance: Studies in Single Brain Neurons. *Mol Pharmacol* **32**:633-638.

Dang VC, Williams JT (2004) Chronic Morphine Treatment Reduces Recovery from Opioid Desensitization. *J Neurosci* **24**: 7699-7706. <https://doi.org/10.1523/JNEUROSCI.2499-04.2004>.

Dang VC, Williams JT (2004) Morphine-Induced μ -Opioid Receptor Desensitization. *Mol Pharmacol* **68**: 1127-1132. <https://doi.org/10.1124/mol.105.013185>.

Fiorillo CD, Williams JT (1996) Opioid Desensitization: Interactions with G-Protein-Coupled Receptors in the Locus Coeruleus. *J Neurosci* **16**: 479-1485 <https://doi.org/10.1523/jneurosci.16-04-01479.1996>.

Gillis A, Gondin AB, Kliewer A, Sanchez J, Lim HD, Alamein C, Manandhar P (2020) Low Intrinsic Efficacy for G Protein Activation Can Explain the Improved Side Effect Profiles of New Opioid Agonists. *Science Signaling* **13** (625): eaaz3140.
<https://doi.org/10.1126/scisignal.aaz3140>.

Gillis A, Kliewer A, Kelly E, Henderson G, Christie MJ, Schulz S, Cannals M (2020) Critical Assessment of G Protein-Biased Agonism at the μ -Opioid Receptor. *Trends Pharmacol Sci* **41**: 947–59. <https://doi.org/10.1016/j.tips.2020.09.009>.

Günther, T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp H, Lupp A (2018). International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. *Pharmacol Rev* **70**: 763–835.

<https://doi.org/10.1124/pr.117.015388>.

Gurevich VV, Gurevich EV (2019) GPCR Signaling Regulation: The Role of GRKs and Arrestins. *Frontiers Pharmacol* **10**: 125. <https://doi.org/10.3389/fphar.2019.00125>.

Harris GC, Williams JT (1991) Transient Homologous μ -Opioid Receptor Desensitization in Rat Locus Coeruleus Neurons. *J Neurosci* **11**: 2574-2581. <https://doi.org/10.1523/jneurosci.11-08-02574.1991>.

He L, Gooding SW, Lewis E, Felth LC, Gaur A, Whistler JL (2021) Pharmacological and Genetic Manipulations at the M-Opioid Receptor Reveal Arrestin-3 Engagement Limits Analgesic Tolerance and Does Not Exacerbate Respiratory Depression in Mice. *Neuropsychopharmacol* July. <https://doi.org/10.1038/s41386-021-01054-x>.

Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall K, Mundells S, Bailey CP, Kelly E, Henderson G (2006) Agonist-Selective Mechanisms of μ -Opioid Receptor Desensitization in Human Embryonic Kidney 293 Cells. *Mol Pharmacol* **70**: 676-685. <https://doi.org/10.1124/mol.106.022376>.

Kliwer A, Schmiedel F, Sianati S, Bailey A, Bateman JT, Levitt ES, Williams JT, Christie MJ, Schulz S (2019) Phosphorylation-Deficient G-Protein-Biased μ -Opioid Receptors Improve Analgesia and Diminish Tolerance but Worsen Opioid Side Effects. *Nature Com* **10**: 367. <https://doi.org/10.1038/s41467-018-08162-1>.

Leff ER, Arttamangkul S, Williams JT (2020) Chronic Treatment with Morphine Disrupts Acute Kinase-Dependent Desensitization of GPCRs. *Mol Pharmacol* **98**: 497-507. <https://doi.org/10.1124/mol.119.119362>.

Levitt ES, Williams JT (2012) Morphine Desensitization and Cellular Tolerance Are Distinguished in Rat Locus Coeruleus Neurons. *Mol Pharmacol* **82**: 983-992.

<https://doi.org/10.1124/mol.112.081547>.

Madia PA, Dighe SV, Sirohi S, Walker E, Yoburn BC (2009) Dosing Protocol and Analgesic Efficacy Determine Opioid Tolerance in the Mouse. *Psychopharmacol* **207**: 413-422.

<https://doi.org/10.1007/s00213-009-1673-6>.

Matthes H, Maldonado WDR, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K (1996) Loss of Morphine-Induced Analgesia, Reward Effect and Withdrawal Symptoms in Mice Lacking the μ -Opioid-Receptor Gene. *Nature* **383**: 819-823 <https://doi.org/10.1038/383819a0>.

Melief EJ, Miyatake M, Bruchas MR, Chavkin C (2010) Ligand-Directed c-Jun N-Terminal Kinase Activation Disrupts Opioid Receptor Signaling. *Proc Nat Acad Sci* **107**: 11608-11613.

<https://doi.org/10.1073/pnas.1000751107>

Morgan MM, MacDonald CJ (2011) Analysis of Opioid Efficacy, Tolerance, Addiction and Dependence from Cell Culture to Human: Opioid Efficacy, Tolerance and Addiction. *Brit J Pharmacol* **164**: 1322-1334. <https://doi.org/10.1111/j.1476-5381.2011.01335.x>.

Pawar M, Kumar K, Sunkaraneni S, Sirohi S, Walker EA, Yoburn BC (2007) Opioid Agonist Efficacy Predicts the Magnitude of Tolerance and the Regulation of μ -Opioid Receptors and Dynamin-2. *Eur J Pharmacol* **563**: 92-101. <https://doi.org/10.1016/j.ejphar.2007.01.059>

Virk MS, Arttamangkul S, Birdsong WT, Williams JT (2009) Buprenorphine Is a Weak Partial Agonist That Inhibits Opioid Receptor Desensitization. *Journal of Neuroscience*.

<https://doi.org/10.1523/JNEUROSCI.3723-08.2009>.

Virk MS, Williams JT (2008) Agonist-Specific Regulation of μ -Opioid Receptor Desensitization and Recovery from Desensitization. *Mol Pharmacol* **29**: 7341-7348.

<https://doi.org/10.1124/mol.107.042952>

Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, MacDonald CJ (2013). Regulation of μ -Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance. *Pharmacol Rev* **65**: 223-254.

<https://doi.org/10.1124/pr.112.005942>.

Yousulf A, Miess E, Sianati S, Du YP, Schulz S, MacDonald CJ (2015) Role of Phosphorylation Sites in Desensitization of μ -Opioid Receptor. *Mol Pharmacol* **88**: 825-835.

<https://doi.org/10.1124/mol.115.098244>

Footnote:

This work was supported by National Institutes of Health Grants RO1 DA004523 and T32 DA007262 (Williams) and Achievement Rewards for College Scientist (Adhikary).

No author has an actual or perceived conflict of interest below the references.

Figure 1. Decreased sensitivity to ME after Chronic fentanyl but not oxycodone treatment.

(A) Representative trace showing outward currents induced by [ME in a slice from an untreated animal. (B) Representative trace from a fentanyl treated animal. (C) Concentration response curve of ME normalized to UK14304 (3 μ M) in slices from untreated (black circle), oxycodone treated (gray circle), and fentanyl treated animals (blue circle). In slices from untreated animals the EC₅₀ was 166 nM (95% CI=152-297 nM, N = 3,5 cells/concentration). There was a twofold rightward shift in the concentration response curve in slices from fentanyl treated (EC₅₀ fentanyl treated animals: 518 nM, 95% CI=496-644 nM, N = 3, 5 cells per concentration). The concentration response in slices from oxycodone treated animals was not changed relative to untreated animals (179 nM, 95% CI=117-280 nM, N = 3, 5 cells/concentration).

Figure 2. Oxycodone concentration response curves

(A) Representative trace showing GIRK channel currents induced by oxycodone (1 μ M) and reversal by naloxone. (1 μ M), followed by UK14304 (3 μ M) and reversal by idaxozan (1 μ M). (B) Representative trace showing oxycodone induced current in a slice from oxycodone treated and oxycodone-maintained animal. Application of naloxone (1 μ M) revealed the oxycodone current, followed by UK14304 (3 μ M) and reversal by idaxozan (1 μ M). (C) Oxycodone concentration response curves normalized to UK14304 (3 μ M) current in slices from untreated animals (black circle) and oxycodone treated animals (gray circle). There were no differences in oxycodone induced currents between untreated and oxycodone treated animals, (EC₅₀ untreated: 2.5 μ M (95% CI=1.1-5.5 μ M, N = 3, 5 cells/concentration; EC₅₀ oxycodone-treated animals: 4.5 μ M; 95% CI=1.4-16.1 μ M, N = 3, 4 cells/concentration). Additionally, summary of oxycodone induced current in slices maintained in oxycodone treatment normalized to UK14303 (3 μ M; gray square). The current induced by oxycodone (1 μ M) was not different between slices from untreated, oxycodone treated and oxycodone treated maintained in oxycodone (untreated, 35.8 $\pm$ 7.4 % of UK14304, oxycodone treated, 34.9 $\pm$ 6.1% OF UK14304, oxycodone treated maintained in oxycodone, 34.5 $\pm$ 11.3 % of UK14304).

Figure 3. Morphine induced current is decreased in slices from fentanyl but not oxycodone treated animals. (A) Representative trace showing the current induced by morphine (1 μ M), reversed by naloxone (1 μ M), followed by UK14303 (3 μ M), reversed by idaxozan (1 μ M) in a slice from an untreated animal. (B) Representative trace showing the morphine induced current in a slice from an oxycodone treated animal. (C) Representative trace showing the current induced by morphine in a slice from a fentanyl treated animal. (D) Summary data of morphine induced currents normalized to UK14303 induced currents from untreated animals (black circle, N=11 cells from 3 male and 3 female), oxycodone treated animals (gray circle, N=7 cells from 3 male and 2 female), and fentanyl treated animals (blue circles, N=10 cells from 4 male and 3 female). Chronic fentanyl treatment, but not chronic oxycodone treatment, significantly reduced morphine induced current, $p < .05$, one way ANOVA followed by a Turkey test).

Figure 4. Increased MOR desensitization by ME after chronic fentanyl but not oxycodone. (A) Representative trace showing the current induced by ME (10 μ M; 2 minutes) followed by morphine (10 μ M) and reversed by naloxone (1 μ M). Morphine induced current is normalized to current induced by UK14303 (3 μ M). (B) Representative trace showing the morphine induced current following ME (10 μ M; 2 minutes) in a slice from a fentanyl treated animal. (C) Summary showing oxycodone induced current after ME (10 μ M, 2 min) in slices from untreated animals (black circle, N=6) and oxycodone treated animals (gray circles, N=5) and fentanyl treated animals (blue circles, N=6). There was no change in desensitization MORs between untreated and oxycodone treated animals ($p > 0.05$, unpaired t-test), but the morphine induced current was decreased in slices from fentanyl treatment animals compared to untreated controls ($p < 0.05$, unpaired t-test).

Figure 5. Compound 101 blocks desensitization induced by SST in slices from buprenorphine and fentanyl treated animals but not after treatment with morphine or oxycodone.

(A) Representative trace of the current induced by SST (10 μ M; 10 min) in a slice from an oxycodone treated animal in control (left) and after treatment with compound 101 (right). (B) Representative trace of the SST induced current in a slice from a fentanyl treated animal in control (left) and after treatment with compound 101 (right). (C) Summary of the % decline. From the peak current induced by SST (10 μ M, 10 min) in slices from (from left to right)

untreated, morphine treated, oxycodone treated, buprenorphine treated and fentanyl treated animals with and without compound 101. Compound 101 was effective in reducing the decline in current in slices from untreated, buprenorphine and fentanyl treated animal but not in morphine or oxycodone treated animals.

Figure 6. Compound 101 is effective after morphine treatment in MOR knockout animals.

(A) Representative trace the current induced by SST (10 μ M; 10 mins) in a slice from an untreated animal in control (left) and after treatment with compound 101 (right) in a MOR KO animal. (B) Representative trace of the current induced by SST (10 μ M; 10 mins) in a slice from a morphine treated animal in control (left) and after treatment with compound 101 (right). (C) Summary of % decline from the peak current induced by SST (10 μ M; 10 mins) in slices from an untreated (left) and morphine treated animals. In MOR KO animals compound 101 reduced SST induced desensitization in both untreated animals (open circles, N=7) and morphine related animals (open circles, N=6).

Figure 7. Compound 101 no longer blocks the decline in SST current in animals that express the TPD MOR.

(A) Representative trace the current induced by SST (10 μ M; 10 mins) in a slice from an untreated animal in control (left) and after treatment with compound 101 (right) in a MOR KO animal expressing TPD MORs. (B) Representative trace of the current induced by SST (10 μ M; 10 mins) in a slice from a fentanyl treated animal in control (left) and after treatment with compound 101 (right). (C) Summary of % decline from the peak current induced by SST (10 μ M; 10 mins) in slices from an untreated (left) and fentanyl treated animals. In animals expressing the TPD MOR, compound 101 reduced SST induced desensitization in untreated animals (open circles, N=5) and compound 101 was ineffective at blocking SST induced desensitization in slices from fentanyl treated animals (open circles, N=7).

Figure 1

Figure 3

Figure 4

Figure 5

Figure 6

Somatostatin desensitization in MOR KO

Figure 7